



Exploring Breast Cancer Gene Mutations using Next Generation Sequencing Technique

Ogawa Abe*

Department of Genetic Engineering and Biotechnology, Osaka University, Suita, Japan

DESCRIPTION

Glioblastoma is a type of aggressive brain cancer that is difficult to treat and has a poor prognosis. It is the most common and most aggressive form of brain cancer, and its treatment is often unsuccessful. While some treatments, such as radiation and chemotherapy, have been used to slow the progression of the disease, they are not always effective. As a result, there is a need to explore new options for treating glioblastoma. Next Generation Sequencing (NGS) is a technique that can be used to sequence the Breast Cancer Gene (*BRCA*) genes, which are associated with glioblastoma. By using NGS can better understand how glioblastoma develops and identify potential targets for therapeutic intervention. Additionally, NGS can help to identify mutations that may be driving tumor growth, which can help inform the development of more effective treatments.

Recent advances in NGS technology have made it possible to sequence the entire *BRCA* gene sequence, as well as other genes that have been linked to glioblastoma. This has enabled to more accurately identify potential targets for treatment and to develop novel therapies that are tailored to each patient's unique tumor. In addition, NGS can be used to monitor the effectiveness of treatments in real-time and to identify patients who may benefit from targeted therapies. By continuing to advance NGS technology and its applications for glioblastoma treatment, can continue to make strides towards improving outcomes for patients. In doing so, they can help to create more effective treatments for an incredibly challenging disease.

Next Generation Sequencing (NGS) is a revolutionary technology that allows sequencing the entire genomes of organisms in a much faster and more efficient way than ever before. This technology is allowing scientists to gain an unprecedented level of insight into the genetic makeup of organisms and better understand the genetic basis of disease. One area where NGS is particularly useful is in the diagnosis and treatment of glioblastoma, an aggressive form of brain cancer. By sequencing the *BRCA* genes, which are associated with glioblastoma can better understand the genetic basis of the disease

and look for potential targets for treatment. By sequencing other genes that have been linked to the disease, can gain additional insight into the genetic basis of glioblastoma and develop more effective treatments for the disease. In summary, next generation sequencing is an invaluable tool for advancing the diagnosis and treatment of glioblastoma. By sequencing the *BRCA* genes, can gain a better understanding of the genetic basis of the disease and develop more effective treatments. Additionally, by sequencing other genes associated with glioblastoma, can gain further insight into the genetic basis of the disease and develop more effective treatments.

Glioblastoma is an aggressive form of brain cancer that is difficult to treat. Fortunately, recent has suggested that sequencing *BRCA* genes can provide valuable insights into the treatment of glioblastoma. Using Next-Generation Sequencing (NGS) technology, scientists are able to examine the *BRCA1* and *BRCA2* genes, which have been associated with an increased risk of certain cancers, including glioblastoma. By identifying specific mutations and pathways that are involved in tumor growth, scientists can develop novel therapies that are tailored to the individual needs of each patient. Finally, sequencing *BRCA* genes can provide insights into the genetic mechanisms that are involved in glioblastoma progression. By understanding the genetic basis of glioblastoma, doctors may be able to develop better treatments and preventative measures. Overall, sequencing *BRCA* genes is an important step towards advancing glioblastoma treatment. By providing valuable insights into tumor genetics, drug targets, and progression, NGS technology can help improve the lives of those affected by this aggressive form of cancer.

Next Generation Sequencing (NGS) is an essential tool for advancing the study and treatment of glioblastoma, a highly aggressive form of brain cancer. By sequencing the *BRCA* genes, can gain valuable insights into how glioblastoma develops and how it can be best treated. However, there are several challenges and limitations when it comes to using NGS to sequence *BRCA* genes. One of the main challenges is cost. NGS is an expensive technology, and it can be difficult to access the resources necessary

Correspondence to: Ogawa Abe, Department of Genetic Engineering and Biotechnology, Osaka University, Suita, Japan, Email: ogawab@gmail.jp

Received: 03-Apr-2023, Manuscript No. RDT-23-21224; **Editor assigned:** 07-Apr-2023, PreQC No. RDT-23-21224 (PQ); **Reviewed:** 21-Apr-2023, QC No. RDT-23-21224; **Revised:** 28-Apr-2023, Manuscript No. RDT-23-21224 (R); **Published:** 05-May-2023, DOI: 10.35248/2329-6682.23.12.230

Citation: Abe O (2023) Exploring Breast Cancer Gene Mutations using Next Generation Sequencing Technique. Gene Technol. 12:230.

Copyright: © 2023 Abe O. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

to conduct a successful sequencing project. Additionally, NGS requires a significant amount of time and effort to prepare samples, process the data, and interpret the results. Another challenge is accuracy. In addition to accuracy, NGS can be limited by the number of samples it can process in a given amount of time. Sequencing large numbers of samples at once can be difficult and time-consuming, and can lead to data overload. Finally, NGS can be limited by the availability of quality samples. Next Generation Sequencing (NGS) of *BRCA*

genes is providing a breakthrough in the understanding and treatment of glioblastoma.

By detecting genetic mutations in *BRCA* genes, doctors are able to identify which treatments are most likely to be effective for individual patients. This helps to ensure that patients receive the best care possible and can lead to improved outcomes. Although NGS of *BRCA* genes is a relatively new technology, it is already proving to be a powerful tool in the fight against glioblastoma.